The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.u

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

Publications

Bhatnagar M, Agaronov A, Sarkisyan E, Sotoudeh Deilamy I, Pepito D, Akhondi H

Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.

International journal of rheumatic diseases 2023 Jul 14;; — 2023 Jul 14

Acharya I, Weisman DS, Smith LW, Arend LJ

Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.

BMJ case reports 2023 Jul 10;16; — 2023 Jul 10

Khosla AA, Saunders H, Helgeson S, Hikida H, Aslam N, Salem F, Albadri S, Baig H

The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis.

Case reports in pulmonology 2023;2023;1461011 — 2023 — 1461011

Warren K, Vu K, Shergill K, Watson B, Faris M

Rare complication of a commonly used antihypertensive agent: A case of hydralazine-induced ANCA-associated vasculitis presenting as rapidly progressive glomerulonephritis.

Clinical case reports 2022 Feb;10;e05411 — 2022 Feb — e05411

Russe-Russe JR, Pellegrini JR, Alvarez-Betancourt A, Munshi RF, Anand P

Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use.

Cureus 2021 Oct;13;e18974 — 2021 Oct — e18974

Battisha A, Doughem K, Sheikh O, Konduru L, Madoukh B, Al-Sadawi M, Shaikh S

Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.

Current cardiology reviews 2020 May 17;; — 2020 May 17

Schrom KP, Field HE, Chang T, Montanez-Wiscovich ME

Antineutrophil cytoplasmic antibody vasculitis induced by hydralazine.

Cutis 2020 Jan;105;E32-E35 — 2020 Jan — E32-E35

Baradhi KM

An intriguing case of anemia and renal failure.

Proceedings (Baylor University. Medical Center) 2019 Jan;32;78-79 — 2019 Jan — 78-79

Paley MA, Edrees F, Kudose S, Gaut JP, Ranganathan P, Vijayan A

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2019 Jan-Feb;30;226-230 — 2019 Jan-Feb — 226-230

Zuckerman R, Patel M, Costanzo EJ, Dounis H, Haj RA, Seyedali S, Asif A

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis.

Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 2018 Apr-Jun;40;193-197 — 2018 Apr-Jun — 193-197

Babar F, Posner JN, Obah EA

Hydralazine-induced pauci-immune glomerulonephritis: intriguing case series with misleading diagnoses.

Journal of community hospital internal medicine perspectives 2016;6;30632 — 2016 — 30632

Agarwal G, Sultan G, Werner SL, Hura C

Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome.

Case reports in nephrology 2014;2014;868590 — 2014 — 868590

Pendergraft WF, Niles JL

Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.

Current opinion in rheumatology 2014 Jan;26;42-9 — 2014 Jan — 42-9

Keasberry J, Frazier J, Isbel NM, Van Eps CL, Oliver K, Mudge DW

Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report.

Journal of medical case reports 2013 Jan 14;7;20 — 2013 Jan 14 — 20

Marina VP, Malhotra D, Kaw D

Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.

International urology and nephrology 2012 Dec;44;1907-9 — 2012 Dec — 1907-9

Dobre M, Wish J, Negrea L

Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review.

Renal failure 2009;31;745-8 — 2009 — 745-8

Sangala N, Lee RW, Horsfield C, Goldsmith DJ

Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.

International urology and nephrology 2010 Jun;42;503-6 — 2010 Jun — 503-6

Yokogawa N, Vivino FB

Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.

Modern rheumatology 2009;19;338-47 — 2009 — 338-47

Choi HK, Merkel PA, Walker AM, Niles JL

Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.

Arthritis and rheumatism 2000 Feb;43;405-13 — 2000 Feb — 405-13

Short AK, Lockwood CM

Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.

QJM : monthly journal of the Association of Physicians 1995 Nov;88;775-83 — 1995 Nov — 775-83